incretin mimetic agents glp 1 receptor agonists GLP-1 and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits Clinical Focus on GLP-1 Agonists
Description
Different peptides
It covers one of the same receptor pathways but eliminates the GIP component, which may be responsible for your specific side effects
At the time the protocols were finalized, trial results for SURPASS-CVOT were not yet available
"The important factor is that some weight was not regained, and when you look at the loss from baseline weight, it's about 4% to 5% of the baseline weight that was lost and maintained
GLP-1 agonists and risk of suicidal thoughts and behaviours: confound by indication once again
